Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Safety and Tolerability of the Vaginal Gel PRO 2000/5

A Phase I Multicenter Dose Escalation Safety and Acceptability Study of the Investigational Vaginal Microbicide Agent PRO 2000/5 Gel (P)

The purpose of this study is to determine whether the vaginal gel PRO 2000/5 causes irritation when used daily.

Studies have shown PRO 2000/5 is safe and well tolerated as a vaginal gel in healthy women who are not sexually active. However, it was not determined what side effects to skin in the vaginal area there might be in sexually active women.

Studieöversikt

Status

Avslutad

Betingelser

Intervention / Behandling

Detaljerad beskrivning

Vaginal microbicides are designed to inhibit the sexual transmission of HIV-1 and other disease pathogens. Two Phase I clinical trials were conducted to evaluate the safety and tolerance of the gel, PRO 2000/5, in sexually abstinent volunteers. Both demonstrated that multiple application of the gel was safe and well tolerated in healthy, sexually abstinent women but no clear association between the use of the gel and epithelial disruption was indicated. Because genital ulceration and inflammation may increase the risk of HIV infection, additional clinical evaluation of PRO 2000/5 gel is warranted, especially for study participants with active sexual behavior.

Participants apply PRO 2000/5 gel intravaginally either once or twice daily for 14 days. HIV-negative participants in sexually active cohorts (Cohorts A1-A4) are instructed to engage in vaginal intercourse at least twice a week. Participants in the HIV-positive cohort (Cohort B1) abstain from sexual intercourse for the dosing period. Researchers conduct physical exams to see if the gel is having any harmful effects on the woman's vulva, vagina, or cervix. Women and their male partners are questioned about gel usage.

Studietyp

Interventionell

Inskrivning

60

Fas

  • Fas 1

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

    • North Carolina
      • Research Triangle Park, North Carolina, Förenta staterna, 27709
        • Julia Welch

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år till 45 år (Vuxen)

Tar emot friska volontärer

Ja

Kön som är behöriga för studier

Kvinna

Beskrivning

Inclusion Criteria

Volunteers may be eligible for this study if they:

  • Are female and 18-45 years of age.
  • Are willing and able to complete daily study records.
  • Are willing to undergo clinical exams and testing.
  • Either have regular menstrual periods or do not menstruate due to use of hormones.
  • Agree to stop using female barrier methods of birth control during the study.
  • Additionally, volunteers may be eligible for HIV-negative groups in this study if they:
  • Have not changed their use of hormonal birth control over the last 3 months.
  • Are HIV-negative.
  • Have a single male partner at low-risk for HIV infection and agree that he can be asked for his consent.
  • Agree to the following: To have vaginal intercourse 2 or more times a week; to use condoms provided by the study for each act of intercourse; to use the gel as directed; not to be in similar studies; not to receive oral sex; not to use IV drugs, except for medical treatment; not to use any other vaginal products; not to douche; and not to use vaginal drying agents.
  • Additionally, volunteers may be eligible for the HIV-positive group in this study if they:
  • Are HIV-positive.
  • Have a CD4 count greater than 200 cells/mm3.
  • Have a normal Pap smear at screening.
  • Are on stable anti-HIV drug therapy.
  • Agree to have no sexual intercourse during the study.
  • Have HIV care by qualified medical caregivers.
  • Agree to allow study staff access to their HIV medical care information.
  • Agree to the following: To use the gel as directed; not to use IV drugs other than for medical treatment; not to use any other vaginal products; not to participate in similar studies; not to receive oral sex; not to douche; and not to use any vaginal drying agents.

Exclusion Criteria

Volunteers will not be eligible for this study if they:

  • Are menopausal.
  • Have certain liver, kidney, or blood problems.
  • Have genital problems such as sores.
  • Are allergic to anything used in the study, including latex.
  • Have used spermicides or condoms treated with spermicides within the week before enrollment.
  • Have been in another drug study within the past 30 days.
  • Have participated in this trial before and study gel has been permanently discontinued.
  • Have had an IUD or begun using hormonal birth control, or had an abnormal Pap smear, a pregnancy, an abortion, gynecologic surgery, breakthrough menstrual bleeding, or vaginal bleeding during or following sexual intercourse, in the last 3 months.
  • Have had or received treatment for sexually transmitted diseases in the past 3 months.
  • Show signs, on a pelvic exam, indicating a sexually transmitted disease or other genital tract problems.
  • Used IV drugs, except for medical reasons, within the past year.
  • Received antibiotics in the last 14 days.
  • Have had a reaction to an anticoagulant (such as warfarin or heparin).
  • Are pregnant or breast-feeding.
  • Have a positive urine culture.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Förebyggande

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Samarbetspartners

Utredare

  • Studiestol: Ken Mayer
  • Studiestol: Salim Abdool Karim

Publikationer och användbara länkar

Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studieregistreringsdatum

Först inskickad

11 september 2000

Först inskickad som uppfyllde QC-kriterierna

30 augusti 2001

Första postat (Uppskatta)

31 augusti 2001

Uppdateringar av studier

Senaste uppdatering publicerad (Uppskatta)

30 juli 2008

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

29 juli 2008

Senast verifierad

1 juni 2003

Mer information

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Kliniska prövningar på HIV-infektioner

Kliniska prövningar på PRO 2000

3
Prenumerera